IGFBP2 and breast carcinoma: Indeed, the protease-resistant IGFBP2 inhibits MCF-7 human breast cancer cell proliferation in vitro, and when it is combined with a non-matrix-binding mutation, the IGFBP2 mutant more effectively inhibits the growth and angiogenesis of MCF-7 tumor xenograft in vivo (30).